{
    "2018-12-14": [
        [
            {
                "time": "",
                "original_text": "股获券商买入评级 瑞康医药目标涨幅达48.51%",
                "features": {
                    "keywords": [
                        "瑞康医药",
                        "券商",
                        "买入评级",
                        "目标涨幅"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业周报:仿制药迎变局,把握确定性投资机会",
                "features": {
                    "keywords": [
                        "医药生物",
                        "仿制药",
                        "变局",
                        "确定性投资机会"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}